Hormone Therapy
Peer-reviewed research on testosterone replacement, hormone optimization, and related therapies for men.
Hormone therapy in the context of men's health refers to the clinical use of exogenous hormones or hormone-modulating agents to restore, replace, or suppress endogenous hormone levels. The most commonly discussed form is testosterone replacement therapy (TRT), prescribed to men with clinically low testosterone levels confirmed through laboratory testing and accompanied by consistent symptoms. However, the broader category also includes estrogen-modulating therapies, growth hormone interventions, DHEA supplementation, thyroid hormone optimization, and androgen deprivation therapy used in the management of prostate cancer. Each of these carries distinct mechanisms, indications, and risk profiles.
Testosterone plays a central role in regulating body composition, bone density, erythropoiesis, sexual function, mood, and cognitive performance in men. Levels decline gradually with age, and a subset of men experience symptoms significant enough to affect daily functioning and long-term health outcomes. The clinical relevance extends beyond quality of life. Low testosterone has been associated in observational research with increased risks of metabolic syndrome, type 2 diabetes, cardiovascular events, and all-cause mortality, though the nature of these associations (causal versus correlational) remains an active area of investigation. Hormone therapy, when appropriately prescribed and monitored, has the potential to address measurable deficiencies. At the same time, inappropriate or unsupervised use carries risks that are still being defined with greater precision by ongoing research.
Early research on testosterone therapy focused primarily on its effects on sexual function and libido, with relatively short follow-up periods and small sample sizes. Over time, study designs became more rigorous, and the scope of outcomes investigated expanded to include cardiovascular health, bone mineral density, cognitive function, mood disorders, and body composition changes. The Testosterone Trials (TTrials) and subsequent large-scale efforts represented a meaningful shift toward coordinated, placebo-controlled investigation across multiple endpoints. These programs helped clarify which outcomes respond reliably to testosterone therapy and which remain uncertain.
The cardiovascular safety profile of testosterone therapy has been one of the most scrutinized questions in men's health research over the past two decades. Early observational studies and a small number of trials raised concerns about increased cardiovascular risk, prompting regulatory agencies to issue safety warnings and mandate further investigation. More recent large-scale randomized trial data have provided a more nuanced picture, suggesting that testosterone therapy in men with documented hypogonadism may not carry the elevated cardiovascular risk previously feared, and may in some contexts offer modest protective effects. However, the evidence base is still maturing, and questions remain about long-term outcomes beyond current trial durations, effects in older populations with pre-existing cardiovascular disease, and optimal dosing strategies.
Several controversies continue to shape clinical practice and research priorities. The diagnostic threshold for hypogonadism itself is debated, with no universal agreement on the testosterone level that warrants treatment, particularly when symptoms are nonspecific or overlap with aging, depression, or obesity. The distinction between age-related decline and pathological deficiency remains contentious. Concerns about the impact of exogenous testosterone on fertility, prostate health, and polycythemia risk inform prescribing decisions but are supported by evidence of varying quality. The growing use of testosterone therapy in younger men, often obtained outside traditional clinical settings, raises additional questions about long-term safety and the potential for dependence on exogenous sources after suppression of endogenous production.
The subtopics below examine specific aspects of hormone therapy in greater detail, including testosterone replacement protocols, fertility preservation strategies during therapy, monitoring and lab interpretation, emerging therapies such as selective androgen receptor modulators, and the evidence surrounding hormone optimization in specific populations like aging men and those with metabolic comorbidities.
Research on this site
- Total papers indexed
- 24
- Meta-analyses
- 0
- Randomized trials
- 0
- Reviews
- 0
Common Questions
What is testosterone replacement therapy and who is it for?
Testosterone replacement therapy (TRT) is a medical treatment that restores testosterone levels in men diagnosed with hypogonadism, a condition defined by consistently low serum testosterone (typically below 300 ng/dL) combined with clinical symptoms such as fatigue, reduced libido, or loss of muscle mass. It is not indicated for men with age-related testosterone decline alone unless accompanied by confirmed deficiency and symptoms. Diagnosis requires at least two morning fasting blood tests, as levels fluctuate throughout the day.
What are the risks of testosterone replacement therapy?
Known risks of TRT include erythrocytosis (elevated red blood cell count), which increases clotting risk, as well as suppression of natural testosterone production and impaired sperm production, leading to reduced fertility. Cardiovascular risk remains an active area of research, with some studies suggesting potential concern in men with pre-existing heart disease, while other large trials have found no significant increase in major adverse cardiac events. Regular monitoring of hematocrit, PSA, and cardiovascular markers is standard clinical practice during treatment.
Does testosterone therapy cause prostate cancer?
Current evidence does not establish that TRT causes prostate cancer in men without pre-existing disease. The long-standing 'androgen hypothesis' that higher testosterone drives prostate cancer growth has largely been replaced by the 'saturation model,' which suggests prostate tissue becomes saturated at relatively low androgen levels. TRT is contraindicated in men with active or suspected prostate cancer, and regular PSA monitoring is recommended for all men on therapy.
What forms of testosterone replacement therapy are available?
TRT is available in several delivery methods including intramuscular or subcutaneous injections (testosterone cypionate or enanthate), transdermal gels or patches, buccal patches, nasal gels, and subcutaneous pellets. Injections tend to produce larger peaks and troughs in serum testosterone levels, while gels and pellets provide more stable concentrations. The choice of formulation depends on patient preference, adherence likelihood, cost, and clinical factors such as skin sensitivity or proximity to women or children for topical forms.
Does hormone therapy affect fertility in men?
Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing LH and FSH signaling to the testes, which significantly decreases or halts sperm production in most men. This effect is generally reversible after discontinuation, but recovery time varies and can take six months to over two years. Men who wish to preserve fertility are typically advised to consider alternatives such as clomiphene citrate or human chorionic gonadotropin (hCG), which stimulate endogenous testosterone production without suppressing spermatogenesis.
How long does it take for testosterone therapy to work?
The timeline for symptom improvement varies by outcome: libido and energy often show changes within three to six weeks, while improvements in mood and depressive symptoms may take three months. Changes in body composition, such as increased lean mass and reduced fat mass, typically require three to six months of consistent therapy. Full effects on bone mineral density may not be measurable for up to two years, and not all symptoms respond equally or in every patient.
What is the difference between testosterone therapy and anabolic steroid use?
Medically supervised TRT uses testosterone formulations at doses calibrated to restore physiological serum levels within the normal reference range, under regular laboratory monitoring. Anabolic-androgenic steroid (AAS) abuse involves supraphysiological doses, often of multiple compounds including synthetic derivatives not used clinically, with the goal of enhancing performance or body composition beyond normal limits. AAS misuse carries substantially greater health risks including severe cardiovascular remodeling, hepatotoxicity with certain oral agents, and prolonged or permanent suppression of natural hormone production.
Key Studies
[Evolution of views on the etiology and pathogenesis of lower urinary tract symptoms for men].
LUTS in men is an interdisciplinary problem involving systemic hormonal and metabolic disorders, with testosterone deficiency playing a role in pathogenesis and testosterone replacement therapy showin
Testosterone replacement therapy and spermatogenesis in reproductive age men.
Testosterone replacement therapy suppresses spermatogenesis by inhibiting gonadotropins and reducing intratesticular testosterone, with variable recovery kinetics after cessation, though medical thera
Indications for testosterone therapy in men.
Three large randomized controlled clinical trials have reported new data allowing for a more nuanced, personalized approach to testosterone therapy in middle-aged and older men with functional hypogon
Osteoporosis in men with hypogonadism because of ApoA-I Leu75Pro amyloidosis under long-term testosterone therapy.
Men with hypogonadism because of Apo A-I Leu75Pro amyloidosis under long-term TRT had a high burden of low bone mass (64%) and VFs (almost 15%), with osteopenia-osteoporosis more frequently observed i
Direct conversion from long-acting testosterone replacement therapy to Natesto allows for spermatogenesis resumption: Proof of concept.
Hypogonadal men on long-acting TRT interested in resumption of spermatogenesis may convert directly to Natesto for an opportunity to do so while remaining on a form of TRT and achieving lower E2 level
Approach to the Young Male Patient Who Abuses Androgens: Harm Reduction as a Clinical Strategy.
A dual strategy—supporting cessation where possible while mitigating harm where possible—offers a realistic and ethical response to the growing population of androgen abusers and aims to bridge the cu
Hormone Therapy: Testosterone Replacement Therapy.
Testosterone replacement therapy (TRT) is indicated for men with hypogonadism defined by low serum total testosterone (<300-350 ng/dL on two separate morning samples) plus signs or symptoms, with mana
Cardiovascular effects of metformin and testosterone replacement therapy in older men with hormone-related cancers and cancer-free population.
Metformin and testosterone replacement therapy were both inversely associated with cardiovascular disease risk among older men in the overall population, hormone-related cancer survivors, and cancer-f